Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $5.00.
Silvan Tuerkcan has given his Buy rating due to a combination of factors that highlight Taysha Gene Therapies’ promising advancements and financial stability. The company has made notable strides in its regulatory interactions, particularly in the areas of Chemistry, Manufacturing, and Controls (CMC) and initial pivotal plans. This progress is underscored by the positive safety profile reported for the high-dose patients, with no serious adverse events or dose-limiting toxicities observed.
Additionally, Taysha Gene Therapies is well-positioned financially, with a cash reserve of $139 million expected to sustain operations into the fourth quarter of 2026. The anticipated clinical updates in the first half of 2025, including detailed pivotal trial designs and endpoint selections, further bolster confidence in the company’s trajectory. The ongoing dialogue with the FDA and the RMAT designation for Rett syndrome also contribute to the optimistic outlook, as these factors are expected to facilitate the development of objective endpoints that demonstrate therapeutic efficacy.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $6.00 price target.